What question did this study set out to answer?

To evaluate the effects of atenolol on survival rates and cardiovascular morbidity in patients at risk for coronary artery disease undergoing noncardiac surgery.

December 5, 1996New England Journal of Medicine

Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac Surgery

View Full Paper

Ask AI

Bookmark

Why the study?

Does atenolol improve overall survival and reduce cardiovascular morbidity in patients with or at risk for coronary artery disease undergoing noncardiac surgery?

Population

200 patients with or at risk for coronary artery disease who were undergoing noncardiac surgery

Comparison

Atenolol given intravenously before and… vs Placebo

Design

RCT, randomized, double-blind, placebo-controlled

Follow-up

two years

Authors

DMDennis T. ManganoCardiac Surgery ELElizabeth L. LayugNational Student Clearinghouse Research Center AWArthur W. WallaceSan Francisco VA Medical Center

Discussion

Member takes

Implication

Supports perioperative atenolol in CAD-risk patients for noncardiac surgery; confirms long-term survival benefit in RCT.

Key Points

To evaluate the effects of atenolol on survival rates and cardiovascular morbidity in patients at risk for coronary artery disease undergoing noncardiac surgery.
Conducted a randomized, double-blind, placebo-controlled trial.
Included patients with or at risk for coronary artery disease undergoing noncardiac surgery (N=200).
Administered atenolol intravenously before and after surgery and orally during hospitalization.
Overall mortality was significantly lower in patients treated with atenolol compared to placebo over two years (10% vs. 21%, P=0.019).
Cardiac-related deaths reduced in the atenolol group during the first six to eight months.
Event-free survival was higher in the atenolol group compared to placebo (83% vs. 68%, P=0.008).

Structured PICO

Does atenolol improve overall survival and reduce cardiovascular morbidity in patients with or at risk for coronary artery disease undergoing noncardiac surgery?

Population

200 patients with or at risk for coronary artery disease who were undergoing noncardiac surgery

Intervention

Atenolol given intravenously before and immediately after surgery and orally thereafter for the duration of hospitalization

Comparator

Placebo

Outcome

Overall survival and cardiovascular morbidity over two yearshard clinical

Perioperative atenolol administration significantly reduces long-term mortality and cardiovascular complications in patients with or at risk for CAD undergoing noncardiac surgery.

Cite This Study

Mangano et al. (1996) studied this question.

synapsesocial.com/papers/6a093107a419c5e264d266db https://doi.org/10.1056/nejm199612053352301

View Full Paper

Ask AI

Bookmark

Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac Surgery

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Effect of Atenolol on Mortality and Cardiovascular Morbidity after Noncardiac Surgery

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider